Pharmacokinetics of 1α,25-Dihydroxyvitamin D3 in Normal Mice after Systemic Exposure to Effective and Safe Antitumor Doses

Publisher： Karger

E-ISSN： 1423-0232|66|1|62-66

ISSN： 0030-2414

Source： Oncology, Vol.66, Iss.1, 2004-03, pp. : 62-66

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Psoriasis Vulgaris with Oral 1α,25‐Dihydroxyvitamin D3

By  

THE JOURNAL OF DERMATOLOGY, Vol. 14, Iss. 1, 1987-02 ,pp. : 59-62

John Wiley & Sons Inc

Access to resources Recommend Favorite

1α,24R‐Dihydroxyvitamin D3 Has an Ability Comparable to That of 1α,25‐Dihydroxyvitamin D3 to Induce Keratinocyte Differentiation

By  

THE JOURNAL OF DERMATOLOGY, Vol. 17, Iss. 11, 1990-11 ,pp. : 707-709

John Wiley & Sons Inc

Access to resources Recommend Favorite

PKPD modelling to predict altered disposition of 1α,25‐dihydroxyvitamin D3 in mice due to dose‐dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 14, 2015-07 ,pp. : 3611-3626

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of 1α,25‐Dihydroxyvitamin D3 on the Transglutaminase Activity of Transformed Mouse Epidermal Cells in Culture

By  

THE JOURNAL OF DERMATOLOGY, Vol. 16, Iss. 1, 1989-02 ,pp. : 7-11

John Wiley & Sons Inc

Access to resources Recommend Favorite

1α,25-Dihydroxyvitamin D3 Attenuates Platelet Activation and the Expression of VCAM-1 and MT1-MMP in Human Endothelial Cells

By  

Cardiology, Vol. 118, Iss. 2, 2011-05 ,pp. : 107-115

Karger

Access to resources Recommend Favorite